Diabetes insipidus is a disorder in which kidney passes an abnormal amount of odourless and dilute urine that causes patients to drink plenty of liquids. Diabetes insipidus is categorized into four types namely; central diabetes insipidus, nephrogenic diabetes insipidus, gestational diabetes insipidus, and dispogenic diabetes insipidus. One of the major complication associated with diabetes insipidus is dehydration in which fluid intake is less than fluid loss. The symptoms of diabetes insipidus include fatigue, dry skin, sluggishness, dizziness, nausea, and confusion. The medications for the treatment of disease include desmopressin and vasopressin. Otsuka Pharmaceutical Co., Ltd. is in the process of developing tolvaptan as a vasopressin V2 receptor antagonist for the treatment of diabetes insipidus. Otsuka Pharmaceutical Co., Ltd., has a pipeline of drug candidates for the treatment of diabetes insipidus.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.